Ropanicant
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ropanicant (SUVN-911) is an investigational new drug under development by Suven Life Sciences Ltd for the treatment of major depressive disorder (MDD) and certain neurological conditions. It acts as an antagonist of the α4β2 nicotinic acetylcholine receptor (nAChR), a target involved in mood regulation and cognitive function. Ropanicant has been shown to increase levels of serotonin and brain-derived neurotrophic factor (BDNF) in the cortex, which may contribute to its antidepressant effects. By modulating neurotransmitter levels—particularly serotonin—it is intended to produce rapid antidepressant effects while minimizing the side effects commonly associated with traditional antidepressants.
Ropanicant (SUVN-911) is an investigational new drug under development by Suven Life Sciences Ltd for the treatment of major depressive disorder (MDD) and certain neurological conditions. It acts as an antagonist of the α4β2 nicotinic acetylcholine receptor (nAChR), a target involved in mood regulation and cognitive function. Ropanicant has been shown to increase levels of serotonin and brain-derived neurotrophic factor (BDNF) in the cortex, which may contribute to its antidepressant effects. By modulating neurotransmitter levels—particularly serotonin—it is intended to produce rapid antidepressant effects while minimizing the side effects commonly associated with traditional antidepressants.
See also
Tebanicline Neonicotinoids
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370748825 under CC BY-SA 4.0; modifications have been made.